The text discusses the role of tumor-associated macrophages (TAMs) in enhancing the effectiveness of immune checkpoint inhibitors (ICIs) for treating colorectal cancer.
It highlights that while ICIs can activate immune responses against tumors, the effectiveness varies among patients based on the interactions between TAMs and the tumor environment.
By understanding and manipulating TAMs, researchers hope to overcome resistance to ICIs and improve treatment outcomes for colorectal cancer patients.